Compare TYRA & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | MLCO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2021 | 2006 |
| Metric | TYRA | MLCO |
|---|---|---|
| Price | $25.94 | $5.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $47.50 | $10.10 |
| AVG Volume (30 Days) | 732.5K | ★ 2.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | N/A | $4.37 |
| P/E Ratio | ★ N/A | $12.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.98 | $5.19 |
| 52 Week High | $40.65 | $10.15 |
| Indicator | TYRA | MLCO |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 49.39 |
| Support Level | $24.88 | $5.27 |
| Resistance Level | $31.57 | $5.71 |
| Average True Range (ATR) | 1.84 | 0.21 |
| MACD | -0.68 | 0.03 |
| Stochastic Oscillator | 7.40 | 48.85 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.